Agilent Technologies Inc. (NYSE: A) saw its shares grow slightly at the beginning of Wednesday’s session. The company says it will present new technologies, scientific collaborations, and integrated workflows supporting cancer research and diagnostics at the American Association for Cancer Research (AACR) Annual Meeting on April 17–22 in San Diego.
At the meeting, Agilent will highlight advances designed to connect discovery research, translational science, and companion diagnostics development, reflecting the growing demand for more integrated approaches across the cancer research continuum.
Among the technologies featured is the BioTek Cytation 9 cell imaging multimode reader, the newest addition to the Cytation series of cell imaging and multimode microplate readers. Cytation 9 is designed to support advanced live cell and endpoint assays by combining automated microscopy with conventional microplate reading in a single system, supporting a range of cell based research applications.
In addition, Agilent will provide an early preview of the upcoming AI enabled software enhancement for the xCELLigence RTCA eSight, designed to bring the same straightforward, objective data analysis long valued in impedance measurements to label free live cell imaging, while supporting more consistent, reproducible results.
Agilent will also highlight its collaboration with Oxford Nanopore Technologies, demonstrating the compatibility of Agilent SureSelect target enrichment chemistry with ONT’s long-read sequencing platforms.
A shares advanced $1.01 to $121.40.
Related Stories
